Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 1.00 |
| ▸ | CA2 | P00918 | 19/20 | 1.00 |
| ▸ | CA9 | Q16790 | 16/20 | 1.00 |
| ▸ | CA4 | P22748 | 15/20 | 1.00 |
| ▸ | CA12 | O43570 | 12/20 | 0.74 |
| ▸ | CA3 | P07451 | 12/20 | 0.74 |
| ▸ | CA6 | P23280 | 12/20 | 0.74 |
| ▸ | CA5A | P35218 | 12/20 | 0.74 |
| ▸ | CA7 | P43166 | 12/20 | 0.74 |
| ▸ | CA13 | Q8N1Q1 | 12/20 | 0.74 |
| ▸ | CA14 | Q9ULX7 | 12/20 | 0.74 |
| ▸ | CA5B | Q9Y2D0 | 12/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22118542 | 0.89 | CA1 (0.80) | CA1CA2CA9CA4CA12 | |
| Propazolamide SCHEMBL1817525 | 0.88 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18475604 | 0.87 | CA1 (0.76) | CA1CA2CA9CA4CA12 | |
| SCHEMBL13740942 | 0.86 | CA2 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18476520 | 0.85 | CA1 (0.78) | CA1CA2CA9CA4CA12 | |
| SCHEMBL16975090 | 0.85 | CA2 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL3793947 | 0.83 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL9674316 | 0.82 | CA1 (0.74) | CA1CA2CA9CA4CA12 | |
| SCHEMBL26259445 | 0.82 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL22118514 | 0.82 | CA1 (0.73) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | claimed |
| US-11913000-B2 | Aptamer therapeutics useful in the treatment of complement-related disorders | IVERIC BIO, INC. (US) | 2024-02-27 | — | — | US | claimed |
| CN-113354547-B | Crystallization process of butamide citrate | 江西善渊药业有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-20220387585-A1 | ADOPTIVE CELL THERAPY USING SPHERICAL NUCLEIC ACIDS (SNAS) | NORTHWESTERN UNIVERSITY | 2022-12-08 | — | — | US | claimed |
| CN-113905738-A | Low dose triple combination formulation | 乔治全球健康研究院 | 2022-01-07 | — | — | CN | claimed |
| CN-112888432-A | Methods for delaying the onset of new onset type 2 diabetes and for slowing the progression of type 2 diabetes and treating type 2 diabetes | 英国达科(莱得海德)制药有限公司-楚歌分公司 | 2021-06-01 | — | — | CN | claimed |
| CN-112690283-A | Herbicidal composition containing phenyl isoxazolines with optical activity and application | 沈阳中化农药化工研发有限公司 | 2021-04-23 | — | — | CN | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0274795-A2 | Process for the carbonylation of olefinically unsaturated compounds with a palladium catalyst | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-07-20 | — | — | EP | claimed |
| EP-0036351-B1 | OPHTHALMIC COMPOSITIONS OF CARBONIC ANHYDRASE INHIBITORS FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1985-01-02 | — | — | EP | claimed |
| EP-0014642-B1 | OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF CARBONIC ANHYDRASE INHIBITORS AND S-(-)-1-(TERT-BUTYLAMINO)-3-(4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)-OXY-2-PROPANOL FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1984-03-21 | — | — | EP | claimed |
| US-4438123-A | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-03-20 | — | — | US | claimed |
| EP-0036351-A2 | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0033042-A1 | Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors | MERCK & CO. INC. (US) | 1981-08-05 | — | — | EP | claimed |
| EP-0014642-A2 | Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1980-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11913000-B2 | Aptamer therapeutics useful in the treatment of complement-related disorders | TTR, RNASE1, CLN6 | CA1 4830/4885CA2 4250/4885CA9 3898/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | CA1 610/4885CA2 585/4885CA9 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.